SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nestel, F. P. Articles by Lapp, W. S. Search for Related Content PubMed PubMed Citation Articles by Nestel, F. P. Articles by Lapp, W. S. Related Collections Immunobiology Phagocytes Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2000, Vol. 96, No. 5, pp. 1836-1843 IMMUNOBIOLOGY Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis Frederick P. Nestel, Robert N. Greene, Krikor Kichian, Premysl Ponka, and Wayne S. Lapp From the Department of Physiology, McGill University, Montreal, Canada; and the Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.     Abstract Top Abstract Introduction Materials and methods Results Discussion References During acute graft-versus-host disease (GVHD) the activation of macrophages (M) is mediated by 2 signals, interferon (IFN)- and bacteria-derived lipopolysaccharide (LPS). A cascade of inflammatory responses that includes the release of mediators of tissue injury follows M activation. Among the tissues characteristically targeted during acute GVHD are epithelial tissues of the skin and gastrointestinal tract that normally undergo continuous proliferation and are therefore sensitive to cytostatic processes. We have investigated whether M can mediate cytostatic mechanisms capable of interrupting cell proliferation during acute GVHD. GVHD was induced in nonirradiated C57BL/6XAF1 (B6AF1) mice by the injection of 60 × 106 (acute GVHD) or 30 × 106 (nonlethal GVHD) C57BL/6 (B6) lymphoid cells. M from animals undergoing acute GVHD could be triggered by normally insignificant quantities of LPS to mediate a cytostatic effect on target cells, resulting in the complete shutdown of cellular proliferation. The same amounts of LPS had no effect on M from normal or syngeneically transplanted animals. M mediated the release of significant quantities of intracellular iron from target cells undergoing cytostasis. Reversal of cytostasis occurred following inhibition of nitric oxide (NO) production by NG-monomethyl-L-arginine (NMMA). Production of NO by LPS-triggered M reflected the severity of GVHD. NO release increased significantly during acute GVHD but was only transiently increased during nonlethal GVHD. The results provide evidence that, as a result of activation during acute GVHD, M produce NO and induce the release of iron from target cells, resulting in a potent cytostatic effect that inhibits cellular proliferation. (Blood. 2000;96:1836-1843) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Graft-versus-host disease (GVHD) is initiated by the interaction of donor T lymphocytes with alloantigens on host tissues and is a frequent complication of allogeneic bone marrow transplantation. In acute GVHD, initiation of the afferent phase of the disease process is followed by a cascade of cellular and cytokine responses, release of inflammatory mediators, the onset of T- and B-cell immunosuppression, and tissue injury.1-4 In contrast to the suppressed state of T and B cells, nonspecific M inflammatory mechanisms become activated. Indeed, a key step in the efferent phase of acute GVHD is the progressive activation or priming of M that results in inflammatory tissue injury, weight loss, and death.4-7 Normal M are primed and release nitric oxide (NO) when exposed to interferon (IFN)-. Further activation or triggering of the primed cells by bacterial endotoxinthat is, lipopolysaccharide (LPS)greatly increases NO production8 and triggers the release of tumor necrosis factor (TNF)-.9 During the development of acute GVHD, increased production of IFN- primes M and initiates the inflammatory reaction of the efferent phase.10,11 LPS entering through the injured intestinal epithelium rapidly intensifies the inflammatory cascade as it comes into contact with and triggers primed M to a fully activated state.4,5,12-14 Sale has proposed that during GVHD, M and/or T cells specifically target proliferating stem cells within the epithelial tissues of the skin and gut.15 Epithelial stem cells within these characteristic target organs appear to be preferentially damaged by unidentified mechanisms during acute GVHD.16-18 Proliferating subpopulations of stem cells maintain the integrity of the organs by continual replacement of cells that are shed or sloughed off. Although epithelial damage may occur as a direct result of cytotoxicity, M-mediated cytostatic mechanisms that target self-renewing stem cells would also cause epithelial lesions by preventing adequate cell replacement. M-mediated cytotoxicity preferentially acts on neoplastic cells,19,20 whereas cytostasis targets processes found in all proliferating cells.21-23 NO produced by activated M mediates cytostasis by inhibiting ribonucleotide reductase, a nonheme iron-containing enzyme essential for DNA synthesis.21-24 It also causes the release of intracellular iron from nonheme iron-containing enzymes that are essential for cellular division and mitochondrial respiration.25-27 In experimental GVHD, treatment with NG-monomethyl-L-arginine (NMMA), a competitive inhibitor of NO synthase (NOS) activity, prevents intestinal pathology28 and reverses suppression of splenic lymphocyte mitogen responses.29,30 These findings indicate that NO contributes to intestinal epithelial injury and immunosuppression, which are both characteristic hallmarks of acute GVHD. To determine whether M act as cytostatic effector cells during acute GVHD, we have examined M isolated from nonirradiated F1 hybrid mice transplanted with parental strain lymphoid cells. The results indicate that during acute GVHD, M mediate a potent cytostatic effect when triggered by normally insignificant amounts of LPS and that cytostasis is accompanied by M-mediated release of intracellular iron from the target cells. M-mediated cytostatic function and NO release during acute GVHD were both blocked by NMMA, an inhibitor of NO synthesis. Levels of NO produced by M, in response to LPS, increased during acute GVHDin marked contrast to the transient increase observed during the course of nonlethal GVHD. Our results demonstrate that, as a result of priming during acute GVHD, M are triggered by LPS to act as cytostatic effector cells through the production and release of NO.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Mice Male C57BL/6 (B6) and C57BL/6xAF1 (B6AF1) mice were bred and maintained under conventional conditions in our laboratory and used at 12 to 18 weeks of age. Reagents and media Monoclonal antimurine IFN- was prepared by ammonium sulfate precipitation of R46A2 supernatants. NMMA and LPS (Escherichia coli 0111:B4) were from Calbiochem Corp (La Jolla, CA). LPS in phosphate-buffered saline (PBS) was sterilized by irradiation (15 000 rad). Sulfanilamide, naphthylethylenediamine dihydrochloride, and sodium nitrite were from Sigma Chemical Co (St Louis, MO), phosphoric acid from BDH Chemicals (Montreal, Quebec, Canada), and concanavalin A (ConA) from Pharmacia (Uppsala, Sweden). RPMI 1640, RPMI 1640-Select-Amine kit, Hank's balanced salt solution (HBSS), PBS (GIBCO, Grand Island, NY) and endotoxin-free fetal calf serum (FCS) (Sterile Systems, Logan, UT) contained less than 50 pg/mL endotoxin as quantified by the Limulus amoebocyte lysate assay (Associates of Cape Cod, Woods Hole, MA). All glassware was heated at 180°C for 4 hours. Recombinant murine TNF- (4 × 104 U/µg) was from Genzyme (Boston, MA). Rat antimurine TNF- was purchased from UBI (Lake Placid, NY). Induction of GVHD Single-cell suspensions of donor spleen and lymph nodes were prepared in HBSS as previously described.4,5 Recipient B6AF1 mice were injected intravenously with 30 × 106 B6 (nonlethal GVHD) or 60 × 106 B6 (acute GVHD) or 60 × 106 B6AF1 (syngeneic transplant) lymphoid cells. GVHD induction was monitored by assaying for suppression of the plaque-forming cell response to sheep red blood cells (SRBCs) as previously described.1,2 Cell lines P815, a DBA/2-derived mastocytoma cell line; L5178Y, a DBA/2-derived lymphoma; MDW4, a DBA/2-derived leukemia cell line; and 3T6, a Swiss mouse embryo fibroblast line, were maintained in RPMI 1640 plus 5%-to-10% FCS (37°C, 5% CO2/air). Cell lines tested mycoplasma-free using indicator 3T6 cells and 6-mercaptopurine deoxyribose (BRL, Gaithersburg, MD). Interferon Mouse ConA supernatant was prepared as a source of IFN- by culturing 3 × 106 B6AF1 spleen cells/mL for 48 hours (37°C, 5% CO2/air) in RPMI 1640, 10% FCS, 5 × 105-mol/L 2-mercaptoethanol, and 5 µg/mL ConA. Treatment of supernatants with R46A2 antimurine IFN- completely inhibited activation of normal M as previously described.4 Charging of apotransferrin with 59Fe Human apotransferrin (iron-free transferrin, Behringwerke AG, Marburg, Germany) was charged with 59Fe as previously described.31 Briefly, 20 mol of sodium citrate per 1 mol of iron was added to [59Fe]ferric chloride (209 MBq/mL; specific activity, 370- to 925-MBq/mg Fe; NEN, Lachine, Quebec, Canada). The [59Fe]ferric citrate was added to apotransferrin at a ratio of 2.2 mol Fe:1 mol transferrin and the volume adjusted to a final concentration of 250 µmol/L transferrin in 0.6 mol/L NaHCO3. After 3 hours at room temperature, the solution was extensively dialyzed against normal saline and then PBS. The 59Fe-transferrin was filter-sterilized and stored at 4°C. M monolayer preparation M monolayers were prepared for NO, iron-release, cytostasis, and cytotoxicity assays as previously described.4,5 Briefly, peritoneal cells collected 3 days after intraperitoneal injection of 1 mL of aged, sterile Brewer's thioglycollate medium (10% wt/vol) (Difco Labs, Detroit, MI) were washed twice, adjusted to 2 × 106 cells/mL in cold HBSS, and 100-µL aliquots plated into 96-well flat-bottom plates (Costar #3596, Rochester Scientific, Rochester, NY). After 1.5 hours at 37°C (5% CO2/air), cultures were washed vigorously 4 times with warm HBSS and appropriate assay medium added. Monolayers consisted of more than 95% M as determined by morphology, Diffquick staining, and phagocytosis of latex beads (Sigma). Nitrite assay M monolayers were cultured in 200 µL of nitrite assay medium (phenol red-free RPMI 1640 containing 1 mmol/L L-arginine, 10% FCS, 10 U/mL penicillin, and 100 µg/mL streptomycin) or nitrite assay medium supplemented as outlined in "Results." After 48 hours at 37°C (5% CO2/air), 100 µL of supernatant was collected from triplicate cultures and nitrite measured as previously described.5,32 Briefly, 100 µL of supernatant was added to 100 µL of Griess reagent (1% sulfanilamide in 5% phosphoric acid mixed 1:1 vol/vol with 0.1% naphthylethylenediamine dihydrochloride) at room temperature and the absorbance read at 550 nm on an enzyme-linked immuosorbent assay plate reader (SLT Labinstruments, Salzburg, Austria). Samples were blanked against supernatant from wells containing the identical reagents without M. Nitrite concentrations were determined using a sodium nitrite standard curve. M cytotoxicity assay M cytotoxic activity was determined as previously described.4,5,33 Briefly, M monolayers were incubated in 100 µL of assay medium either alone or with additional reagents for 4 hours (37°C, 5% CO2/air). Target cells were labeled with 111In by adding 370 kBq of indium [111In]oxine (37 MBq/mL; specific activity, 370 MBq/µg In; Amersham, Oakville, Ontario, Canada) to 7.5 × 106 cells in 0.5 mL of RPMI 1640 plus 10% FCS at room temperature for 10 minutes. The cells were washed 3 times in HBSS, resuspended in assay medium (RPMI 1640 plus 10% FCS, 10 U/mL penicillin, and 100 µg/mL streptomycin), and 104 111In-labeled cells in 100 µL of assay medium plated. After 48 hours (37°C, 5% CO2), plates were centrifuged (5 minutes at 500g) and 100 µL of supernatant counted in a gamma counter (LKB, Turku, Finland). The percent specific radioisotope release was calculated from 6 replicates as follows: [(test cpm  spontaneous cpm)/(total cpm  spontaneous cpm)] × 100. Spontaneous release cultures contained normal M and targets in assay medium. Total cpm (counts per minute) was determined from cultures of 104 labeled target cells in 100 µL of assay medium resuspended with 100 µL of 4% Nonidet P-40 (BDH Chemicals). M-mediated release of iron from dual-labeled target cells MDW4 target cells were dual-labeled with 59Fe and 51Cr by adding 2.5 × 106 cells in exponential growth phase to 10 mL of RPMI 1640 containing 5% FCS and 20 µmol/L 59Fe-transferrin and culturing for 36 hours. 59Fe-labeled cells were washed and labeled with 51Cr by incubating 2 × 106 cells for 1 hour at 37°C with 3.7 MBq [51Cr]sodium chromate (37 MBq/mL; specific activity, 9.25- to 18.5 GBq/mg Cr; NEN). The cells were washed in HBSS and resuspended in assay medium (RPMI 1640, 10% FCS, 10 U/mL penicillin, and 100 µg/mL streptomycin). M monolayers were incubated for 4 hours (37°C, 5% CO2/air) in 100 µL of assay medium or assay medium supplemented as outlined in "Results," and 104 59Fe, 51Cr dual-labeled tumor cells were added in 100 µL of assay medium. After 18 hours (37°C, 5% CO2), 100-µL aliquots of supernatant were counted in a gamma counter using nonoverlapping channels that independently detect the emission spectra of 59Fe and 51Cr. The percent specific release of each isotope was calculated from 4 to 6 replicates as in the M cytotoxicity assay. M cytostasis assay M monolayers were incubated 4 hours in 100 µL of assay medium (RPMI 1640, 10% FCS, 10 U/mL penicillin, and 100 µg/mL streptomycin) or medium containing additional reagents as indicated in "Results" and 104 MDW4 target cells added in 100 µL of assay medium. Separate M and target cell cultures were also prepared. After 36 hours at 37°C (5% CO2/air), cultures were pulsed with 37 kBq/well of [methyl-3H]thymidine (TdR) (NEN), incubated for 12 hours, harvested, and counted on a beta counter (LKB). M-mediated cytostasis was determined from the [3H]TdR incorporation in 6 replicate cultures each of M plus target cells, M alone, and targets alone as follows: [(cpm M + target)/[(cpm M) + (cpm target)]] × 100. In all cases, more than 98% of [(cpm M) + (cpm target)] was accounted for by (cpm target).     Results Top Abstract Introduction Materials and methods Results Discussion References Cytotoxic activity of LPS-triggered M during acute GVHD Acute GVHD occurred following the transplantation of 60 × 106 B6 cells into nonirradiated B6AF1 mice, a transplant combination that differs across the entire major histocompatibility complex. The induction of GVHD in transplanted animals was confirmed by the complete suppression of the antibody response to SRBC, a T-cell- dependent antigen (data not shown), as previously demonstrated.1,2,4,5 Mortality was first observed 16 to 18 days posttransplantation and ranged from 70% to 96% by day 25. During acute GVHD, M are primed and therefore can be triggered by extremely low concentrations of LPS to release TNF- and NO and to express cytotoxic activity against TNF--sensitive target cells.4,5 To determine whether M primed during acute GVHD express alternate mechanisms of cell injury, including NO-mediated killing, we used 3 target cell lines that differ in their sensitivity to M-mediated effector mechanisms. L5178Y cells are killed by activated M through a TNF--mediated mechanism,4 whereas P815 cells are sensitive to M cytotoxic activity mediated by NO.34 In contrast, MDW4 cells are resistant to M-mediated cytotoxicity.33 M isolated from acute GVHD animals 12 to 14 days posttransplantation and then triggered by LPS were able to kill P815 and L5178Y target cells (Table 1). Addition of LPS did not trigger M-mediated lysis of MDW4 targets. Although MDW4 cells were not killed, microscopic examination of the assay wells indicated that the GVHD M appeared to be mediating a cytostatic effect. Unlike the other 2 targets, MDW4 cells were still present on top of monolayers of acute GVHD M triggered with LPS, but they had not proliferated over the 48-hour assay period (data not shown). In contrast, confluent growth of all 3 target cell lines, including MDW4, occurred on LPS-treated normal M as well as on untreated monolayers of acute GVHD M.                                View this table: [in this window] [in a new window]   Table 1. M cytotoxic activity triggered by LPS during acute GVHD LPS-triggered M mediate cytostasis during acute GVHD Normal M activated with IFN- and LPS induce cytostasis in target cells by inhibiting ribonucleotide reductase, a rate-limiting enzyme in DNA replication that contains nonheme iron.21-24 We investigated whether M that are primed during acute GVHD can be triggered by low concentrations of LPS to mediate a cytostatic effect. On day 14 after transplantation, addition of 2.5 ng/mL LPS to acute GVHD M triggered a potent cytostatic effector mechanism, resulting in the complete inhibition of [3H]TdR uptake by MDW4 target cells (Table 2). M isolated from normal B6AF1 or from B6AF1 mice that had received a syngeneic transplant of 60 × 106 B6AF1 cells did not show any evidence of primingthat is, they could not be triggered by LPS. Cytostatic function could not be triggered in these M even when 50 ng/mL LPS was added (data not shown). Expression of cytostatic activity by M from normal or syngeneic transplant recipients was observed only following activation with both IFN- and LPS and was effectively inhibited in the presence of anti-IFN-. In contrast, LPS-triggered cytostatic activity mediated by acute GVHD-primed M was not reduced by anti-IFN-, indicating that the cells had been previously exposed to the initial priming signal.                                View this table: [in this window] [in a new window]   Table 2. M cytostatic activity triggered by LPS during acute GVHD Our observation of cytostasis could be interpreted as resulting from the inhibitory effect of activating agents, such as LPS, on target cell growth. However, [3H]TdR incorporation by target cells in the absence of M was the same whether the cells were grown in medium or medium containing 2.5 ng/mL LPS (Table 2). Although M are able to secrete thymidine,35 which could potentially block the cell cycle or competitively inhibit radiolabeled thymidine uptake, we found that [3H]TdR incorporation was identical for target cells grown in supernatants from cultures of GVHD M grown in either medium alone or in medium containing 2.5 ng/mL LPS (data not shown). LPS-triggered M production of NO is related to the severity of GVHD and time posttransplantation Transplantation of either 30 × 106 or 60 × 106 B6 lymphoid cells into B6AF1 recipients causes tissue injury and immunosuppression of T- and B-cell function.2,4,7 When housed in a conventional environment, animals that receive 60 × 106 B6 cells start dying approximately day 16 to 18 posttransplantation, and most die of acute GVHD by day 25. Transplantation of 30 × 106 B6 cells results in nonlethal GVHD from which the animals eventually recover. We therefore compared mice undergoing acute and nonlethal GVHD on days 7 and 14 to determine whether the levels of NO produced correspond to the severity of GVHD. M production of NO was examined by measuring NO2 (nitrite), the oxidized by-product of NO. NO production could be detected in the culture supernatants of M isolated from either acute or nonlethal GVHD animals after incubation of the cells with 2.5 ng/mL LPS (Table 3). The levels of NO were equivalent in the 2 transplant groups on day 7 after transplantation. By day 14, NO levels were reduced in the nonlethal GVHD group but had more than doubled in the acute GVHD group. M from normal animals released NO only after activation with both IFN- and LPS. Incubation of acute GVHD M with LPS and anti-IFN- as compared with LPS alone did not result in a significant reduction in the amount of NO. Detection of NO2 in culture supernatants was dependent on the presence of L-arginine, indicating that the measured NO2 production resulted from the oxidation of L-arginine, a process involving NO as an intermediate.36                                View this table: [in this window] [in a new window]   Table 3. LPS-triggered M production of NO during acute and nonlethal GVHD LPS triggers M-mediated release of iron from target cells during acute GVHD Normal M that are activated in vitro mediate the release of intracellular iron from nonheme iron-containing enzymes in targets cells, resulting in cytostasis.25-27,37 The release or loss of iron from targets can also be reproduced by authentic NO.38 M primed during acute GVHD produced and released NO when triggered by the same low concentrations of LPS that were found to trigger M cytostatic activity (Tables 2 and 3). We therefore examined whether exposure to similarly low levels of LPS during acute GVHD could trigger M-mediated release of iron from target cells undergoing cytostasis. Dual labeling with 59Fe and 51Cr was used to distinguish between cytostatic mechanisms that selectively mediate the loss of intracellular iron and cytotoxic effects that result in the nonspecific release of 51Cr-labeled cytoplasmic proteins. Target cells were physiologically labeled by growing them in medium containing [59Fe]transferrin, thereby incorporating 59Fe into nonheme iron-containing enzymes. This was followed by nonspecific labeling with [51Cr]sodium chromate. M isolated from acute GVHD animals 14 days posttransplantation could be triggered with 2.5 ng/mL LPS to selectively release 59Fe from dual-labeled target cells without an equivalent release of 51Cr (Table 4). M from normal animals did not selectively cause 59Fe release from targets unless activated with both IFN- and LPS and the activity was inhibited by the addition of anti-IFN- (Table 4). In contrast, iron release mediated by M primed in vivo during GVHD and then incubated with LPS was not significantly reduced by anti-IFN-. Target cells single-labeled with 59Fe and cultured for up to 48 hours in the presence of recombinant TNF-, without any M, did not release iron (Table 4). During acute GVHD, M were triggered by LPS in a dose-dependent manner to induce iron loss from target cells (Figure 1). Only minor variations in release of 51Cr occurred over the same LPS concentration range that triggered 59Fe release, indicating that loss of iron was independent of 51Cr release. As indicated, release of intracellular 59Fe increased steadily over an LPS concentration range of 0.02 to 0.3 ng/mL.                                View this table: [in this window] [in a new window]   Table 4. Release of intracellular iron mediated by LPS-triggered M during acute GVHD View larger version (14K): [in this window] [in a new window]   Figure 1. LPS dose response for M-mediated release of intracellular iron from target cells during acute GVH. Target cell release of 59Fe () and 51Cr () mediated by M from normal B6AF1 mice and release of 59Fe () and 51Cr () mediated by M from acute GVHD B6AF1 mice transplanted 14 days previously with 60 × 106 B6 cells. M-mediated radioisotope release was determined using 59Fe,51Cr dual-labeled MDW4 cells in an 18-hour assay as described in "Materials and methods." Each value represents the mean ± SD of 4 replicates of pooled M effector cells. Similar results were obtained in 2 separate experiments. NO mediates LPS-triggered M cytostatic activity during acute GVHD To determine whether acute GVHD M mediate their cytostatic activity as a result of NO production and release, we studied the effect of inhibiting M synthesis of NO. Accumulation of NO in culture supernatants of LPS-triggered day 14 acute GVHD M was inhibited by the addition of NMMA, a competitive inhibitor of inducible NOS (iNOS) (Figure 2A). Inhibition of the cytostatic effect mediated by LPS-triggered acute GVHD M was also observed in the presence of NMMA. Addition of the inhibitor restored target cell proliferation to approximately 60% (Figure 2B). View larger version (10K): [in this window] [in a new window]   Figure 2. NMMA inhibits NO production and cytostatic activity mediated by acute GVHD-primed, LPS-triggered M. Acute GVHD M () from B6AF1 animals transplanted 14 days previously with 60 × 106 B6 cells were activated with 2.5 ng/mL LPS, and normal M () from B6AF1 animals were activated with 2.5 ng/mL LPS and IFN-. (A) The concentration of NO in 48-hour culture supernatants was determined as described in "Materials and methods." M were cultured in phenol red-free RPMI 1640 containing 1.0 mmol/L L-arginine plus 10% FCS with or without NMMA as indicated. Results represent the mean ± SD of triplicates. Similar results were obtained in 2 separate experiments. (B) M-mediated cytostasis of MDW4 cells was determined as described in "Materials and methods." M and targets were cultured for 48 hours in RPMI 1640 plus 10% FCS containing 1.0 mmol/L L-arginine either with or without NMMA as indicated. Results represent the mean ± SEM of 3 experiments.     Discussion Top Abstract Introduction Materials and methods Results Discussion References In this study, we have examined the cytostatic function of M during the development of GVHD. Our results demonstrate that, as a result of priming during acute GVHD, M mediate a strong cytostatic effect when triggered by normally insignificant amounts of LPS. Cytostasis of target cells, which is accompanied by the release of intracellular iron, can be reversed by inhibition of macrophage NO production. Furthermore, M production of NO in response to LPS reflects the severity of GVHD. During nonlethal GVHD, NO production is transiently increased in contrast to the steadily increased production that occurs during acute GVHD. During the development of acute GVHD, increased production of IFN-,10,11 combined with entry and accumulation of bacteria-derived LPS,4,7,12-14 results in M activation and release of inflammatory products including TNF-, NO, and interleukin (IL)-1.4,5,39 In acute GVHD, injury to the proliferating intestinal epithelium and suppression of lymphocyte proliferation are prevented by inhibitors of NO.28-30 Suppression of ConA-induced lymphocyte proliferation in cocultures of GVHD plus normal splenic lymphocytes can be reversed by depletion of L-leucine methyl ester-sensitive cells expressing M surface markers and intracellular iNOS.40 In human and experimental animal transplant recipients, the symptoms of GVHD are preceded by an increase in serum levels of NO oxidation productsthat is, NO2and NO3.41,42 Authentic NO directly mediates target cell cytostasis by inhibiting a nonheme iron-containing enzyme, ribonucleotide reductase.24 Similarly, normal M activated with both IFN- and LPS produce NO and mediate cytostasis by inhibiting target cell ribonucleotide reductase.21,24 Exposure to increasing amounts of IFN- results in a significant reduction in the amount of LPS needed to trigger M synthesis of inflammatory products.8,9 As a result of IFN- production during the development of acute GVHD, M become primed and, therefore, normally insignificant quantities of LPS trigger production of NO and TNF-.4,5 The cytostatic activity of M during acute GVHD was measured using MDW4, a target cell line that is resistant to M-mediated killing33 (Table 1). Target cell proliferation was completely inhibited by acute GVHD M, and cytostasis could be triggered by concentrations of LPS as low as 2.5 ng/mL (Table 2). Addition of NMMA effectively inhibited NO production by IFN- plus LPS-activated normal M and by LPS-triggered GVHD M (Figure 2A). Cytostatic function was also inhibited by NMMA, although cytostasis mediated by GVHD M was not completely reversed (Figure 2B). NO-independent mechanisms could also contribute to the loss of proliferation.43 Activation of additional cytostatic mechanisms appears to occur during the prolonged in vivo priming period that GVHD M undergo prior to being triggered by LPS. Target organs injured during acute GVHD, including the gut and skin, contain subpopulations of proliferating stem cells that may be particularly sensitive targets of the direct cytostatic effector mechanism(s) mediated by activated M.15-18 We previously demonstrated that the severity of GVHD is directly related to the level of M priming.4 Sensitivity to LPS is much greater during acute than nonlethal GVHD, as shown by the large reduction in LPS needed to induce lethal endotoxic shock and TNF- production.4 A similar relationship was observed for LPS-triggered NO production. In nonlethal GVHD, LPS-triggered M production of NO was observed 7 days after transplantation but was greatly reduced by 14 days (Table 3). In contrast, in acute GVHD, NO production by LPS-triggered M increased between 7 and 14 days posttransplantation. Transient priming of M during nonlethal GVHD probably reflects a decreased level of IFN- production because, without continual priming, the ability of M to be triggered by LPS decays with time.5 During acute GVHD, M generation of NO may be further augmented through an autocrine, positive feedback effect of M-derived TNF-.8 However, addition of neutralizing rat monoclonal or rabbit polyclonal antimurine TNF- to acute GVHD M did not significantly inhibit LPS-triggered NO generation or M-mediated cytostasis (data not shown). Increased IFN- production and priming of M are key steps in the onset and progression of acute GVHD. Clinical bone marrow transplant recipients have more IFN--producing cells, and the symptoms of acute GVHD are preceded by a marked increase in serum IFN- levels and production of neopterin, a cofactor in NO metabolism.10,44 Levels of iNOS expression and NO production in human macrophage lineage cells do not reach the high levels observed in murine macrophages. However, recent studies on human M have convincingly documented iNOS protein and messenger RNA (mRNA) expression as well as NO production under a variety of activation conditions and in several disease states.45 In experimental acute GVHD, the percentage of lymphoid cells expressing IFN- mRNA is significantly increased.46 Transplantations using IFN- knockout donors lead to longer survival times.47 A shift in donor T-cell populations from Th1 to Th2 reduces the number of IFN--producing cells, inhibits ConA-induced NO production by splenocytes, reduces sensitivity to the lethal effects of LPS, and prevents acute GVHD.30,48,49 In acute GVHD, both IFN- and NO mRNA are expressed within target organs, and augmented IFN- expression persists despite the onset of T-cell immunosuppression.5 IL-12 p40 mRNA is also detectable in target organs and in M during acute GVHD, and anti-IL-12 treatment polarizes the recipient cytokine profile to a Th2 type and can prevent acute GVHD.5,50 Activation of effector cells, including natural killer (NK) cells and M, thus appears to be mediated by IL-12-induced IFN- production, allowing for continual priming of M during acute GVHD.5 M-derived and authentic NO inactivate nonheme iron-containing enzymes via the action of NO on iron centers in the molecules. Activated M mediate target cell release of intracellular iron,25-27 losses of iron from nonheme iron-containing mitochondrial enzymes,26,27 and formation of iron-nitrosyl compounds in mitochondria.51 Loss of intracellular iron is directly mediated by NO.38 During acute GVHD, LPS-triggered M mediated the selective release of approximately 40% of intracellular iron from target cells over an 18-hour period (Table 4, Figure 1). Although NO is recognized as a mediator of iron release from target cells, additional M mechanisms may also contribute to release of iron.52 In human transplant recipients, the appearance of bleomycin-reactive, that is, free, nontransferrin-bound plasma iron, is associated with the development of acute GVHD.53 Chemically reactive iron released from target cells can act as a catalyst in the Fenton reaction between hydrogen peroxide and superoxide anions produced by M, resulting in hydroxyl radical formation, and thus could significantly contribute to tissue damage.54 Large numbers of M within the gastrointestinal tract, splenic red pulp, and liver (ie, Kupffer cells) intercept bacteria that enter from the external environment via translocation through the intestinal epithelium.55,56 During the development of GVHD, initial damage to the intestinal epithelium is mediated directly by IFN-57,58 or indirectly via activation of NK or NK-like effector cells.2,59,60 As a result, increased translocation of gram-negative bacteria or bacteria-derived LPS triggers IFN--primed M to produce NO and TNF-, leading to further epithelial injury.4,5,12,13 The barrier function of epithelial tissues can be further compromised by the NO-mediated cytostatic effect of activated M on rapidly proliferating epithelial stem cells in the skin, gut, and liver. Despite the immunosuppression that accompanies GVHD, entry of live gram-negative bacteria can initially be well tolerated and infections avoided as a result of IFN--mediated activation of M bactericidal function.11 Nevertheless, the end result is a progressive accumulation of LPS in the liver and spleen.13 These events initiate an inflammatory cascade of acute-phase secretory products, including NO, TNF-, and IL-1, that participate in pathologic tissue injury.4-7,39 The inflammatory cascade is magnified as the capacity of the liver to bind, detoxify, and excrete LPS becomes saturated and LPS begins to appear in the serum.4,13 LPS entry into the circulation and delivery to target organs further escalates release of inflammatory mediators because of the triggering effect of LPS at sites throughout the body where primed M are found and finally results in septic shock and death.     Acknowledgments We are grateful to Michel Emond, Ailsa Lee Loy, and Rosmarie Siegrist-Johnstone for their expert technical assistance, and we thank Ania Wilczynska and Jane Barraclough for assistance in the preparation of radiolabeled transferrin. We gratefully acknowledge Dr John Hibbs Jr for critical review of the manuscript.     Footnotes Submitted November 11, 1999; accepted May 2, 2000. Supported by grants from the Medical Research Council of Canada. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Frederick Nestel, Department of Physiology, McGill University, McIntyre Medical Sciences Bldg, 3655 Drummond St, Montreal, Quebec, Canada, H3G 1Y6; e-mail:fnestel{at}med.mcgill.ca.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA. The functional and histological basis for graft-versus-host induced immunosuppression. Immunol Rev. 1985;88:107-131[Medline] [Order article via Infotrieve]. 2. Ghayur T, Seemayer TA, Lapp WS. Histological correlates of immune functional deficits in graft-vs-host disease. In Burakoff SJ, Ferrara JLM, Deeg HJ, Atkinson K, eds. Graft-vs-Host Disease. New York, NY: Marcel Dekker; 1990:109-132. 3. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-674[Medline] [Order article via Infotrieve]. 4. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor-alpha during graft-versus-host disease. J Exp Med. 1992;175:405-413[Abstract/Free Full Text]. 5. Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease: possible involvement of IFN-. J Immunol. 1996;157:2851-2856[Abstract]. 6. Krenger W, Hill GR, Ferrara JLM. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553-558[Medline] [Order article via Infotrieve]. 7. Nestel FP, Kichian K, You-Ten K, et al. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease. New York, NY: Marcel Dekker; 1997:501-523. 8. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-2412[Abstract]. 9. Gifford GE, Lohmann-Matthes M-L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst. 1987;78:121-124. 10. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-gamma during human bone marrow transplantation: analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation. 1990;50:620-625[Medline] [Order article via Infotrieve]. 11. Leist TP, Heuchel R, Zinkernagel RM. Increased bactericidal macrophage activity induced by immunological stimuli is dependent on interferon (IFN)-: interference of anti-IFN- but not anti-IFN-/ with modulation of macrophage activity caused by lymphocytic choriomeningitis infection or systemic graft-vs.-host reactions. Eur J Immunol. 1988;18:1295-1298[Medline] [Order article via Infotrieve]. 12. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 1996;8:3230-3239. 13. Price K, Nestel FP, Lapp WS. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand J Immunol. 1997;45:294-300[Medline] [Order article via Infotrieve]. 14. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213[Abstract/Free Full Text]. 15. Sale GE. Does graft-versus-host disease attack epithelial stem cells? Mol Med Today. 1996;2:114-119[Medline] [Order article via Infotrieve]. 16. Sale GE, Beauchamp M. Parafollicular hair bulge in human GVHD. A stem cell-rich primary target. Bone Marrow Transplant. 1993;11:223-225[Medline] [Order article via Infotrieve]. 17. Sale GE, Beauchamp M, Akiyama M. Parafollicular bulges, but not hair bulb keratinocytes, are attacked in graft-versus-host disease of human skin. Bone Marrow Transplant. 1994;14:411-413[Medline] [Order article via Infotrieve]. 18. Fox RJ, Vogelsang GB, Beschorner WE. Denuded bowel after recovery from graft-versus-host disease. Transplantation. 1996;62:1681-1684[Medline] [Order article via Infotrieve]. 19. Fidler IJ. Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sci. 1978;14:177-191[Medline] [Order article via Infotrieve]. 20. Hibbs J Jr. Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst. 1974;53:1487-1492. 21. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 1989;169:1543-1555[Abstract/Free Full Text]. 22. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med. 1991;174:761-767[Abstract/Free Full Text]. 23. Lepoivre M, Flaman J-M, Bobe P, Lemaire G, Henry Y. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide: relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J Biol Chem. 1994;42:1891-1897. 24. Lepoivre M, Fieschi F, Coves J, Thelander L, Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun. 1991;179:442-448[Medline] [Order article via Infotrieve]. 25. Hibbs JB Jr, Taintor RR, Vavrin Z. Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem Biophys Res Commun. 1984;123:716-723[Medline] [Order article via Infotrieve]. 26. Drapier J-C, Hibbs JB Jr. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells: inhibition involves the iron-sulphur prosthetic group and is reversible. J Clin Invest. 1986;78:790-797. 27. Wharton M, Granger DL, Durack DT. Mitochondrial iron loss from leukemia cells injured by macrophages: a possible mechanism for electron transport chain defects. J Immunol. 1988;141:1311-1317[Abstract]. 28. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM. Nitric oxide mediates intestinal pathology in graft-vs-host disease. Eur J Immunol. 1992;22:2141-2145[Medline] [Order article via Infotrieve]. 29. Hoffman RA, Langrehr JM, Wren SM, et al. Characterization of the immunosuppressive effects of nitric oxide in graft-vs-host disease. J Immunol. 1993;151:1508-1518[Abstract]. 30. Krenger W, Falzarano G, Delmonte J, Snyder KM, Byon JCH, Ferrara JLM. Interferon- suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental graft-versus-host disease. Blood. 1996;88:1113-1121[Abstract/Free Full Text]. 31. Martinez-Medellin J, Schulman HM. The kinetics of iron and transferrin incorporation into rabbit erythroid cells and the nature of stromal-bound iron. Biochim Biophys Acta. 1972;264:272-274[Medline] [Order article via Infotrieve]. 32. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138[Medline] [Order article via Infotrieve]. 33. Nestel FP, Casson PR, Wiltrout RH, Kerbel RS. Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage and natural killer cell resistant tumor variants. J Natl Cancer Inst. 1984;73:483-491. 34. Higuchi M, Higashi N, Taki H, Osawa T. Cytolytic mechanisms of activated macrophages: tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J Immunol. 1990;144:1425-1431[Abstract]. 35. Stadecker MJ, Unanue ER. The regulation of thymidine secretion by macrophages. J Immunol. 1979;123:568-571[Abstract/Free Full Text]. 36. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry. 1988;27:8706-8711[Medline] [Order article via Infotrieve]. 37. Granger DL, Lehninger AL. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol. 1982;95:527-535[Abstract/Free Full Text]. 38. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157:87-94[Medline] [Order article via Infotrieve]. 39. Abhyankar S, Gilliland DG, Ferrara JLM. IL-1 is a critical effector molecule during cytokine dysregulation in GVHD to minor histocompatibility antigens. Transplantation. 1993;56:1518-1523[Medline] [Order article via Infotrieve]. 40. Bobe P, Benihoud K, Grandjon D, et al. Nitric oxide mediation of active immunosuppression associated with graft-versus-host disease. Blood. 1999;94:1028-1037[Abstract/Free Full Text]. 41. Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest. 1992;90:679-683. 42. Weiss G, Schwaighofer H, Herold M, et al. Nitric oxide formation as predictive parameter for acute GVHD after human allogeneic bone marrow transplantation. Transplantation. 1995;60:1239-1244[Medline] [Order article via Infotrieve]. 43. Zingarelli B, Virag L, Szabo A, et al. Oxidation, tyrosine nitration and cytostasis induction in the absence of inducible nitric oxide synthase. Int J Mol Med. 1998;1:787-795[Medline] [Order article via Infotrieve]. 44. Velardi A, Varese P, Terenzi A, et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood. 1989;74:1665-1672[Abstract/Free Full Text]. 45. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med. 1998;4:557-591[Medline] [Order article via Infotrieve]. 46. Troutt AB, Kelso A. Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc Natl Acad Sci U S A. 1992;89:5276-5280[Abstract/Free Full Text]. 47. Ellison CA, Fischer JMM, HayGlass KT, Gartner JG. Murine graft-versus-host disease in an F1-hybrid model using IFN- gene knockout donors. J Immunol. 1998;161:631-640[Abstract/Free Full Text]. 48. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine GVHR. J Immunol. 1994;152:1004-1013[Abstract]. 49. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994;84:3540-3549[Abstract/Free Full Text]. 50. Williamson E, Garside P, Bradley JA, More IAR, Mowat AM. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol. 1997;159:1208-1215[Abstract]. 51. Drapier JC, Pellat C, Henry Y. Generation of EPR-detectable nitrosyl-iron complexes in tumor target cells cocultured with activated macrophages. J Biol Chem. 1991;266:10162-10167[Abstract/Free Full Text]. 52. Klostergaard J. Monokine mediated release of intracellular iron in tumor target cells in vitro. Lymphokine Res. 1987;6:19-28[Medline] [Order article via Infotrieve]. 53. Foerder CA, Tobin AA, McDonald GB, Zager RA. Bleomycin-detectable iron in plasma of bone-marrow transplant patients: its correlation with liver injury. Transplantation. 1992;54:1120-1123[Medline] [Order article via Infotrieve]. 54. Halliwell B, Gutteridge JMC. Biologically relevant metal ion-dependent hydroxyl radical generationan update. FEBS Lett. 1992;307:108-112[Medline] [Order article via Infotrieve]. 55. Hume DA, Robinson AP, MacPherson GG, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoeitic organs. J Exp Med. 1983;158:1522-1536[Abstract/Free Full Text]. 56. Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues: immunocytochemical studies with monoclonal antibody F4/80. J Exp Med. 1985;161:475-489[Abstract/Free Full Text]. 57. Mowat AM. Antibodies to IFN- prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989;68:18-23[Medline] [Order article via Infotrieve]. 58. Adams RA, Planchon SM, Roche JK. IFN- modulation of epithelial barrier function: time course, reversibility, and site of cytokine binding. J Immunol. 1993;150:2356-2363[Abstract]. 59. Ghayur T, Seemayer TA, Kongshavn PAL, Gartner JG, Lapp WS. Graft-versus-host reactions in the beige mouse: an investigation of the role of natural killer cells in the pathogenesis of GVH disease. Transplantation. 1987;44:261-267[Medline] [Order article via Infotrieve]. 60. Ghayur T, Xenocostas A, Seemayer TA, Lapp WS. Induction, specificity and elimination of asialo-GM1+ graft-versus-host effector cells of donor origin. Scand J Immunol. 1991;34:497-508[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. M. Heinonen, N. Dube, A. Bourdeau, W. S. Lapp, and M. L. Tremblay Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling PNAS, February 21, 2006; 103(8): 2776 - 2781. [Abstract] [Full Text] [PDF] D. Hongo, J. S. Bryson, A. M. Kaplan, and D. A. Cohen Endogenous Nitric Oxide Protects against T Cell-Dependent Lethality during Graft-versus-Host Disease and Idiopathic Pneumonia Syndrome J. Immunol., August 1, 2004; 173(3): 1744 - 1756. [Abstract] [Full Text] [PDF] K. Sun, L. A. Welniak, A. Panoskaltsis-Mortari, M. J. O'Shaughnessy, H. Liu, I. Barao, W. Riordan, R. Sitcheran, C. Wysocki, J. S. Serody, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib PNAS, May 25, 2004; 101(21): 8120 - 8125. [Abstract] [Full Text] [PDF] K. M. Heinonen, F. P. Nestel, E. W. Newell, G. Charette, T. A. Seemayer, M. L. Tremblay, and W. S. Lapp T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease Blood, May 1, 2004; 103(9): 3457 - 3464. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nestel, F. P. Articles by Lapp, W. S. Search for Related Content PubMed PubMed Citation Articles by Nestel, F. P. Articles by Lapp, W. S. Related Collections Immunobiology Phagocytes Transplantation Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020